"omega-N-Methylarginine" is a descriptor in the National Library of Medicine's controlled vocabulary thesaurus,
MeSH (Medical Subject Headings). Descriptors are arranged in a hierarchical structure,
which enables searching at various levels of specificity.
A competitive inhibitor of nitric oxide synthetase.
| Descriptor ID |
D019323
|
| MeSH Number(s) |
D12.125.068.050.650 D12.125.095.104.650 D12.125.142.087.500
|
| Concept/Terms |
omega-N-Methylarginine- omega-N-Methylarginine
- omega N Methylarginine
- NG-Monomethyl-L-Arginine
- NG Monomethyl L Arginine
- L-NMMA
- L-Monomethylarginine
- L Monomethylarginine
- N(G)-Monomethylarginine
- D-NMMA
- N(G)-Monomethyl-D-Arginine
- N(omega)-Monomethyl-L-Arginine
- L-NG-Monomethyl Arginine
- Arginine, L-NG-Monomethyl
- L NG Monomethyl Arginine
- N(G)-Methylarginine
|
Below are MeSH descriptors whose meaning is more general than "omega-N-Methylarginine".
Below are MeSH descriptors whose meaning is more specific than "omega-N-Methylarginine".
This graph shows the total number of publications written about "omega-N-Methylarginine" by people in this website by year, and whether "omega-N-Methylarginine" was a major or minor topic of these publications.
To see the data from this visualization as text,
click here.
| Year | Major Topic | Minor Topic | Total |
|---|
| 1997 | 0 | 1 | 1 |
| 1998 | 0 | 1 | 1 |
| 2001 | 0 | 1 | 1 |
| 2004 | 1 | 0 | 1 |
| 2013 | 0 | 1 | 1 |
| 2015 | 0 | 1 | 1 |
| 2016 | 1 | 0 | 1 |
| 2017 | 1 | 0 | 1 |
To return to the timeline,
click here.
Below are the most recent publications written about "omega-N-Methylarginine" by people in Profiles.
-
Stewart JM, Sutton R, Kothari ML, Goetz AM, Visintainer P, Medow MS. Nitric oxide synthase inhibition restores orthostatic tolerance in young vasovagal syncope patients. Heart. 2017 11; 103(21):1711-1718.
-
Stewart JM, Suggs M, Merchant S, Sutton R, Terilli C, Visintainer P, Medow MS. Postsynaptic a1-Adrenergic Vasoconstriction Is Impaired in Young Patients With Vasovagal Syncope and Is Corrected by Nitric Oxide Synthase Inhibition. Circ Arrhythm Electrophysiol. 2016 08; 9(8).
-
Lakowski TM, Pak ML, Szeitz A, Thomas D, Vhuiyan MI, Clement B, Frankel A. Arginine methylation in yeast proteins during stationary-phase growth and heat shock. Amino Acids. 2015 Dec; 47(12):2561-71.
-
Lee J, Martinez N, West K, Kornfeld H. Differential adjuvant activities of TLR7 and TLR9 agonists inversely correlate with nitric oxide and PGE2 production. PLoS One. 2015; 10(4):e0123165.
-
Gamboa A, Okamoto LE, Raj SR, Diedrich A, Shibao CA, Robertson D, Biaggioni I. Nitric oxide and regulation of heart rate in patients with postural tachycardia syndrome and healthy subjects. Hypertension. 2013 Feb; 61(2):376-81.
-
Terajima M, Leporati AM. Role of Indoleamine 2,3-Dioxygenase in Antiviral Activity of Interferon-gamma Against Vaccinia Virus. Viral Immunol. 2005; 18(4):722-9.
-
L?pez A, Lorente JA, Steingrub J, Bakker J, McLuckie A, Willatts S, Brockway M, Anzueto A, Holzapfel L, Breen D, Silverman MS, Takala J, Donaldson J, Arneson C, Grove G, Grossman S, Grover R. Multiple-center, randomized, placebo-controlled, double-blind study of the nitric oxide synthase inhibitor 546C88: effect on survival in patients with septic shock. Crit Care Med. 2004 Jan; 32(1):21-30.
-
Nagata K, Marb?n E, Lawrence JH, Donahue JK. Phosphodiesterase inhibitor-mediated potentiation of adenovirus delivery to myocardium. J Mol Cell Cardiol. 2001 Mar; 33(3):575-80.
-
Doherty JC, McMillen MA. Use of animal models to test novel therapies in sepsis. Crit Care Med. 2000 Jan; 28(1):287-8.
-
Mannick JB, Stamler JS, Teng E, Simpson N, Lawrence J, Jordan J, Finberg RW. Nitric oxide modulates HIV-1 replication. J Acquir Immune Defic Syndr. 1999 Sep 01; 22(1):1-9.